|
Elliot F. Hahn, Ph.D. has served on our board of directors since August 2004. Dr. Hahn is chairman and chief executive officer of SoLapharm Inc., a pharmaceutical company, since December 2007 and was President of Accu-Break Pharmaceuticals, Inc. since October 2004. He also co-founded Andrx Corporation, a specialty pharmaceutical company acquired by Watson Pharmaceuticals, Inc. in November, 2006. Dr. Hahn was president of Andrx from 1993 until 2003. He served as chairman of the board from 2002 to June 2003, and as interim chief executive officer from 2001 to June 2002. From June 1989 to February 1993, Dr. Hahn served as vice president for scientific affairs of IVAX, a manufacturer and distributor of generic pharmaceutical products acquired by Teva Pharmaceutical Industries Ltd. in January, 2006, where he was involved in the evaluation and licensing of product opportunities, and was responsible for maintaining IVAX�s intellectual property. Prior to that, he was vice president of research at the pharmaceutical subsidiary of IVAX. Before joining IVAX, Dr. Hahn was an associate professor at The Rockefeller University, an assistant professor at Albert Einstein College of Medicine, and a member of the Institute for Steroid Research at Montefiore Hospital. In addition to CyDex, Dr. Hahn serves as a director of Pharmasset, Inc., a pharmaceutical company, and NationsHealth, Inc., a provider of diabetes supplies. He holds a bachelor�s degree from City College of New York and a doctorate in organic chemistry from Cornell University. | 